Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines

Sunil S. RaikarAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia

http://orcid.org/0000-0003-2903-9542

Lauren C. FleischerAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia;Department of Molecular and Systems Pharmacology, Graduate Division of Biological and Biomedical Sciences, Emory University School of Medicine, Atlanta, Georgia

http://orcid.org/0000-0003-0670-0481

Robert MootAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia;Department of Molecular and Systems Pharmacology, Graduate Division of Biological and Biomedical Sciences, Emory University School of Medicine, Atlanta, Georgia

Andrew FedanovAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia

Na Yoon PaikAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia

Kristopher A. KnightAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia

Christopher B. DoeringAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia;Department of Molecular and Systems Pharmacology, Graduate Division of Biological and Biomedical Sciences, Emory University School of Medicine, Atlanta, Georgia

H. Trent SpencerAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia;Department of Molecular and Systems Pharmacology, Graduate Division of Biological and Biomedical Sciences, Emory University School of Medicine, Atlanta, GeorgiaCorrespondence[email protected]

show all

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Xavier Thomas. (2023) T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development. Expert Opinion on Investigational Drugs 32:1, pages 37-52.
Read now

Mina Hosseini, Zahra Habibi, Narges Hosseini, Sina Abdoli & Nima Rezaei. (2022) Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review. Expert Opinion on Biological Therapy 22:3, pages 349-366.
Read now

Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, Sabine Tejpar, Peter Vandenberghe, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Abhishek D. Garg. (2020) Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology 9:1.
Read now

Yuta Ito, Shinichi Makita & Kensei Tobinai. (2019) Development of new agents for peripheral T-cell lymphoma. Expert Opinion on Biological Therapy 19:3, pages 197-209.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines

Citations (4)

Read on this site (4)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date